Results 21 to 30 of about 8,614,068 (306)
Tissue factor controversies [PDF]
Thrombosis Research, 2012 Tissue factor plays a primary role in both hemorrhage control and thrombosis depending upon whether its presentation is extravascular or intravascular. The molecular architecture and function of the tissue factor molecule and its role in the activations of factor IX and factor X have been elegantly elucidated but controversies prevail with respect to ...
Kenneth G, Mann +2 more
openaire +2 more sources
Tissue factor as a potential coagulative/vascular marker in relapsing-remitting multiple sclerosis
Frontiers in Immunology, 2023 ObjectivesRecent studies supported coagulation involvement in multiple sclerosis, an inflammatory-demyelinating and degenerative disease of the central nervous system. The main objectives of this observational study were to identify the most specific pro-
Tatiana Koudriavtseva +21 more
doaj +1 more source
Thrombogenic and Inflammatory Reactions to Biomaterials in Medical Devices
Frontiers in Bioengineering and Biotechnology, 2020 Blood-contacting medical devices of different biomaterials are often used to treat various cardiovascular diseases. Thrombus formation is a common cause of failure of cardiovascular devices.
Carlos A. Labarrere +2 more
doaj +1 more source
Heat shock inhibits lipopolysaccharide-induced tissue factor activity in human whole blood [PDF]
, 2007 Background During gram-negative sepsis, lipopolysaccharide (LPS) induces tissue factor expression on monocytes. The resulting disseminated intravascular coagulation leads to tissue ischemia and worsens the prognosis of septic patients.
Thielmann, Matthias +11 more
core +1 more source
Thrombosis Journal, 2005 Background Thrombin generation assay was developed several years ago to mimic physiological coagulation mechanisms but it had important limitations. Thrombogram-Thrombinoscope assay using a fluorogenic substrate, allows obtaining thrombin generation ...
Leflem Lena +5 more
doaj +1 more source
Comparison of the coagulopathies associated with COVID‐19 and sepsis
Research and Practice in Thrombosis and Haemostasis, 2021 Background Coronavirus disease 2019 (COVID‐19) is associated with activation of coagulation that mainly presents as thrombosis. Sepsis is also associated with activation of coagulation that mainly presents as disseminated intravascular coagulation.
Robert A. Campbell +8 more
doaj +1 more source
Tissue Factor Encryption [PDF]
Arteriosclerosis, Thrombosis, and Vascular Biology, 2006 Tissue factor (TF) encryption is the post-translational suppression of TF procoagulant activity (PCA) on the cell surface. There is emerging evidence of encrypted TF in normal blood associated with monocytes and platelets. Expression of this latent TF PCA during the propagation phase of blood coagulation may contribute to hemostasis.
openaire +2 more sources
Research and Practice in Thrombosis and Haemostasis, 2022 Background Circulating tissue factor (TF)‐expressing extracellular vesicles (EVs) are associated with thrombosis in several diseases, such as coronavirus disease 2019 (COVID‐19). Activity assays have higher sensitivity and specificity compared to antigen
Sierra J. Archibald +3 more
doaj +1 more source
Journal of Cardiovascular Development and Disease, 2022 Background: Thrombosis with cardiovascular involvement is a crucial complication in COVID-19 infection. COVID-19 infects the host by the angiotensin converting enzyme-2 receptor (ACE2r), which is expressed in endothelial cells too.
Giovanni Cimmino +9 more
doaj +1 more source
Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients [PDF]
, 2001 Patients with scleroderma receiving Iloprost as a treatment for severe Raynaud's phenomenon report a reduction in skin tightness, suggesting that this drug inhibits skin fibrosis.
Stratton, R +27 more
core +1 more source